Rodriguez-Lozano F, Onate-Sanchez R, Gonzalvez-Garcia M, Valles-Bergada M, Martinez C, Revilla-Nuin B
J Clin Med. 2020; 9(6).
PMID: 32486396
PMC: 7355877.
DOI: 10.3390/jcm9061649.
Ogata K, Matsumura M, Moriyama M, Katagiri W, Hibi H, Nakamura S
JBMR Plus. 2018; 2(2):69-80.
PMID: 30283893
PMC: 6124208.
DOI: 10.1002/jbm4.10013.
Oteri G, Campisi G, Panzarella V, Morreale I, Nucera R, Di Fede O
Biomed Res Int. 2018; 2018:4021952.
PMID: 30003097
PMC: 5996467.
DOI: 10.1155/2018/4021952.
Bush L, Chew F
Radiol Case Rep. 2016; 3(4):232.
PMID: 27303562
PMC: 4897555.
DOI: 10.2484/rcr.v3i4.232.
Yoshiga D, Nakamichi I, Yamashita Y, Yamamoto N, Yamauchi K, Nogami S
J Clin Exp Dent. 2014; 6(1):e22-8.
PMID: 24596631
PMC: 3935901.
DOI: 10.4317/jced.51213.
An in vitro assessment of fibroblast and osteoblast response to alendronate-modified titanium and the potential for decreasing fibrous encapsulation.
Hu X, Neoh K, Shi Z, Kang E, Wang W
Tissue Eng Part A. 2013; 19(17-18):1919-30.
PMID: 23540949
PMC: 3725798.
DOI: 10.1089/ten.TEA.2012.0218.
Bisphosphonates cause osteonecrosis of the jaw-like disease in mice.
Bi Y, Gao Y, Ehirchiou D, Cao C, Kikuiri T, Le A
Am J Pathol. 2010; 177(1):280-90.
PMID: 20472893
PMC: 2893671.
DOI: 10.2353/ajpath.2010.090592.
Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice.
Kikuiri T, Kim I, Yamaza T, Akiyama K, Zhang Q, Li Y
J Bone Miner Res. 2010; 25(7):1668-79.
PMID: 20200952
PMC: 3154005.
DOI: 10.1002/jbmr.37.
Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs.
Allen M, Kubek D, Burr D
J Bone Miner Res. 2009; 25(1):98-105.
PMID: 19580463
PMC: 3153321.
DOI: 10.1359/jbmr.090713.
Systematic review of trends in prophylaxis of corticosteroid-induced osteoporosis: the need for standard audit guidelines.
Duyvendak M, Naunton M, van Roon E, Bruyn G, Brouwers J
Osteoporos Int. 2008; 19(10):1379-94.
PMID: 18629573
DOI: 10.1007/s00198-008-0598-y.
Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment.
Allen M, Burr D
J Oral Maxillofac Surg. 2008; 66(5):987-94.
PMID: 18423290
PMC: 2464292.
DOI: 10.1016/j.joms.2008.01.038.
Intermittent bisphosphonate therapy in postmenopausal osteoporosis: progress to date.
Reginster J, Malaise O, Neuprez A, Jouret V, Close P
Drugs Aging. 2007; 24(5):351-9.
PMID: 17503893
DOI: 10.2165/00002512-200724050-00001.
